Organization (Other)
Li Min
ClinicalTrials.gov lists Li Min as lead sponsor of 10 trials. It has 4 active development programs.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Rows recorded per section
19 sections measured, none recorded
This page covers Li Min: 10 lead-sponsored trials and 0 legal-entity registrations.
Disease areas (12)
Shown in this order: most trials first.
| Disease area | Trials |
|---|---|
| Atherosclerosis | 1 |
| Back Pain | 1 |
| Carcinoma, Non-Small-Cell Lung | 1 |
| Colorectal Neoplasms | 1 |
| Fractures, Bone | 1 |
Showing 5 of 12 disease areas.
Trials by start year as sponsor or collaborator (3)
Shown in this order: most recent first. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
| Year | Trials started |
|---|---|
| 2026 (partial year) | 6 |
| 2025 | 1 |
| 2019 | 3 |
No forecast is made for this organization: it averages 1.4 trial starts a year over the five years to September, under the 5 a year the method needs.
Recruitment duration, a model prediction: 1 trial still running at the 2026-10-09 snapshot, fewer than the 5 needed for a median. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
The series also counts trials where the organization is a collaborator; the lead-sponsor trial count does not.
Active development programs (4)
Shown in this order: max phase, then active trials.
| Drug | Disease area | Max phase | Trials |
|---|---|---|---|
| Standard of care systemic therapy | Carcinoma, Non-Small-Cell Lung | Phase 2 | 1 |
| Standard of care systemic therapy | Lung Neoplasms | Phase 2 | 1 |
| Standard of care systemic therapy | Colorectal Neoplasms | Phase 2 | 1 |
| Immune Checkpoint Inhibitors | Recurrence | Phase 2 | 1 |
Latest dated events (10)
Shown in this order: newest first.
| Date | Event | Source |
|---|---|---|
| 2026-02 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-02 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-01 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-01 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-01 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
Showing 5 of 10 events.
Biomarker capability evidence (3)
Shown in this order: tier desc, then gene symbol.
| Gene | Role | Evidence |
|---|---|---|
| FOLH1 | Trial sponsor | Named in trial inclusion criteria |
| FOLH1 | Trial sponsor | Exploratory endpoint in a trial |
| FOLH1 | Trial sponsor | Mentioned in trial text |
Not on this page
Checked, with nothing recorded for this organization: companies grouped under this page, related companies not grouped here, approved assets, sponsor delivery record, journals published in, us granted patents, sec-reported annual financials, financing and grant events, fda warning letters, fda untitled letters, fda inspection record, fda recalls, fda import refusals, manufacturing and distribution sites, climate targets, as filed, workforce and board diversity, as filed, organization relationships, clia clinical laboratory certificates, and biomarkers this organization publishes on.